Application of chiral gold nanomaterials targeting NF-κB pathway in the preparation of anti-inflammatory drugs

Chiral gold nanomaterials were prepared by one-step synthesis method, targeting the NF-κB pathway to reduce inflammatory factors, solving the problems of antibiotic abuse and poor stability of natural extracts in antiseptic drugs, and achieving high-efficiency and low-toxic anti-inflammatory effects.

CN118593541BActive Publication Date: 2024-11-26HANGZHOU INST FOR ADVANCED STUDY UCAS
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411078376.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-26
Estimated Expiration
2044-08-07

AI Technical Summary

Technical Problem

Existing antiseptic drugs have problems such as bacterial resistance, toxic reactions, and poor extraction efficiency and poor stability of natural extracts due to antibiotic abuse, and nanomaterials are insufficient in vivo stability and biocompatibility, which affects the anti-inflammatory effect.

Method used

A one-step synthesis method is used to prepare chiral gold nanomaterials, and the sulfhydryl group-containing chiral ligand L-glutathione or its enantiomer is mixed to adjust the pH value and temperature to prepare uniform size. Left- or right-handed chiral gold nanomaterials with controllable shapes targeting the NF-κB pathway to reduce the production of inflammatory factors.

Benefits of technology

The high biocompatibility and low biotoxicity of chiral gold nanomaterials have been achieved, which significantly reduces the inflammatory factors inducing LPS, and provides effective anti-inflammatory treatment possibilities, especially the anti-inflammatory effect of L-Nanogold is better through targeting The NF-κB pathway significantly reduces the production of inflammatory factors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118593541B_ABST
    Figure CN118593541B_ABST
Patent Text Reader

Abstract

The present invention discloses an application of a chiral gold nanomaterial targeting the NF-κB pathway in the preparation of an anti-inflammatory drug. The preparation method of the chiral gold nanomaterial comprises: uniformly mixing an aqueous solution of tetrachloroauric acid with a chiral ligand solution containing a thiol group, then dropwise adding a sodium hydroxide solution, and obtaining the chiral gold nanomaterial after incubation treatment. The chiral gold nanomaterial of the present invention has uniform size and controllable shape, has good biocompatibility, low biological toxicity, and anti-inflammatory activity shows chiral differences, and the anti-inflammatory effect of left-handed gold nanoparticles (L-AuNPs) is better. Left-handed gold nanoparticles can target the NF-κB pathway, rather than the MAPK pathway, and significantly reduce the inflammatory factors induced by LPS by reducing the activity of the NF-κB pathway, thereby achieving control of inflammation, and providing a possibility for slowing down or treating inflammation caused by early sepsis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to application of a chiral gold nanomaterial targeting an NF-κB pathway in the preparation of an anti-inflammatory drug. Background Art

[0002] Sepsis is a disease associated with liver dysfunction caused by Gram-negative bacteria, which can cause serious harm to physical health. During the onset of sepsis, immune cells release a large number of inflammatory factors, causing a severe inflammatory response in the body, which in turn leads to a drop in blood pressure, causing vasodilatory shock, and ultimately causing serious damage to the body. Macrophage activation plays a very important role in the pathogenesis of sepsis. Macrophages are one of the innate immune cells, which are widely distributed in peripheral blood and various target organs, and have the phagocytic ability to support the removal of invaders and initiate immune responses. Lipopolysaccharide (LPS) is an effective activator of multiple inflammatory signaling pathways. It can stimulate macrophages to produce a variety of inflammatory mediators by specifically binding to the TLR4 receptor, and is one of the main causes of sepsis. NF-κB is a transcription factor involved in the expression of immune response mediators and key regulators in a variety of inflammatory diseases, and plays a key role in the production of proinflammatory cytokines, including nitric oxide (NO), prostaglandin E2 (PEG2), chemokine ligand 2 (CXCL2), chemokine ligand 4 (CCL4), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Therefore, controlling the activation of the NF-κB pathway is very important for the development of effective treatments for inflammation.

[0003] Antibiotics are currently the main means of clinical treatment for sepsis. However, the abuse of antibiotics can lead to bacterial resistance and toxic reactions, making the infection more difficult to treat.

[0004] Some natural extracts are also used to treat sepsis, such as daphnetin, lycorine and piperine, which have antioxidant, anti-inflammatory and anti-apoptotic effects. Literature reports that daphnetin can inhibit the release of inflammatory factors such as IL-1β and caspase-1 by inhibiting multiple inflammatory signaling pathways such as MAPK and NF-κB, thereby reducing inflammatory reactions and tissue damage and improving the symptoms of inflammatory diseases. However, the application of natural extracts is limited by their low extraction efficiency, poor stability and cumbersome extraction process. In addition, the safety of natural extracts is unclear, which may reduce their therapeutic effects and even cause damage to the body.

[0005] Nanomaterials play a vital role in the anti-inflammatory and antibacterial fields with their excellent physical and chemical properties, such as nanosilver and nanozinc oxide. However, nanosilver and nanozinc oxide have poor stability, poor biocompatibility, and uneven shape and size distribution, which will affect the antibacterial and anti-inflammatory effects of the materials, especially under physiological conditions such as infected wounds or sepsis.

[0006] Gold nanomaterials have great application prospects in the fields of anti-inflammatory and antibacterial, but in actual in vivo experiments, the metabolism of gold nanomaterials is closely related to the surface chemical properties. Bare gold nanoparticles without coating will produce severe aggregation in major target organs such as the liver and spleen, and these accumulations can induce gene mutations and liver necrosis.

[0007] Chirality is a ubiquitous phenomenon in nature. From the composition of inanimate objects to the complex physiological processes in organisms, chiral molecules are involved. These chiral enantiomers function in a highly stable and orderly manner, and have extraordinary significance for various biological events, including cell metabolism, cell fate, and even the evolution of organisms. Introducing chirality into the nanomolecular scale is a hot area of ​​research at present. Recent studies have shown that chiral nanomaterials play an important role in regulating their distribution, absorption and metabolism in the body, as well as immune regulation.

[0008] However, there are no reports on the anti-sepsis effects of chiral glutathione-modified gold nanomaterials. Summary of the invention

[0009] The present invention provides an application of a chiral gold nanomaterial targeting an NF-κB pathway in the preparation of an anti-inflammatory drug. The chiral gold nanomaterial of the present invention has uniform size and controllable shape, has good biocompatibility, low biological toxicity, and exhibits chiral differences in anti-inflammatory activity. It can significantly reduce LPS-induced inflammatory factors by targeting the NF-κB pathway, thus providing a possibility for treating sepsis.

[0010] The technical solution of the present invention is as follows:

[0011] A chiral gold nanomaterial targeting the NF-κB pathway is used in the preparation of an anti-inflammatory drug. The preparation method of the chiral gold nanomaterial comprises: uniformly mixing a tetrachloroauric acid aqueous solution and a thiol-containing chiral ligand solution, then dropwise adding a sodium hydroxide solution, and obtaining the chiral gold nanomaterial after incubation treatment;

[0012] The chiral ligand containing thiol is L-glutathione or its enantiomer.

[0013] Preferably, in the reaction system of the incubation treatment, the molar ratio of tetrachloroauric acid to the chiral ligand is 3-5:1.

[0014] Preferably, sodium hydroxide solution is added dropwise to adjust the pH value of the reaction system to 10-12.

[0015] Reaction temperature is a key factor in controlling the particle size of gold nanomaterials. Preferably, the incubation temperature is 27-40°C.

[0016] More preferably, the incubation temperature is 35-40° C. Under this incubation temperature, the particle size distribution of the prepared chiral gold nanomaterial is uniform.

[0017] Preferably, the incubation time is 10-24 hours; more preferably, it is 10-12 hours.

[0018] After incubation, the free chiral ligand is removed by centrifugation and washing.

[0019] Preferably, the particle size of the chiral gold nanomaterial is 6-8 nm.

[0020] Preferably, the anti-inflammatory drug is a drug for alleviating and / or treating LPS-induced inflammation.

[0021] Further preferably, the anti-inflammatory drug is a drug for relieving and / or treating sepsis.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] (1) The present invention prepares chiral gold nanomaterials by a simple one-step synthesis method, and the preparation method is simple;

[0024] (2) The chiral gold nanomaterials prepared by the present invention have controllable size and shape, good optical activity, stable morphology and uniform size;

[0025] (3) The chiral gold nanomaterials prepared by the present invention have good biocompatibility, low biotoxicity, and anti-inflammatory activity showing chiral differences. L-AuNPs have better anti-inflammatory effects. By targeting the NF-κB pathway, the phosphorylation level of p65 protein is reduced, thereby significantly reducing inflammatory factors, providing a possibility for the treatment of sepsis. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 The particle size distribution diagram of the chiral gold nanomaterials prepared in Comparative Example 1 (a) and Example 1 (b);

[0027] Figure 2 TEM images of L-AuNPs (a), D-AuNPs (b) and DL-AuNPs (c) in Examples 1-3;

[0028] Figure 3The UV spectra (a) and circular dichroism spectra (b) of L-AuNPs, D-AuNPs and DL-AuNPs in Examples 1-3;

[0029] Figure 4 is a graph showing the survival rate of human bronchial epithelial cells (BEAS-2B) treated with L-AuNPs, D-AuNPs and DL-AuNPs in Examples 1-3;

[0030] Figure 5 The graph is a graph showing the changes in the relative level of CXCL2 in mouse mononuclear macrophages (RAW264.7) induced by LPS after treatment with L-AuNPs and D-AuNPs in Examples 1 and 2;

[0031] Figure 6 The graph is a graph showing the changes in the relative level of CCL4 in mouse mononuclear macrophages (RAW264.7) induced by LPS after treatment with L-AuNPs and D-AuNPs in Examples 1 and 2;

[0032] Figure 7 The graph is a graph showing the changes in the relative level of COX-2 in mouse mononuclear macrophages (RAW264.7) induced by LPS after treatment with L-AuNPs and D-AuNPs in Examples 1 and 2;

[0033] Figure 8 The effect of L-AuNPs on the phosphorylation levels of p65 and p38 in Example 1;

[0034] Fig. 9 The graph is a graph showing the changes in IL-1β levels in the serum of sepsis model mice after treatment with L-AuNPs and D-AuNPs in Examples 1 and 2;

[0035] Fig.10 This is a graph showing the changes in TNF-α levels in the serum of sepsis model mice after treatment with L-AuNPs and D-AuNPs in Examples 1 and 2. DETAILED DESCRIPTION

[0036] The present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be pointed out that the embodiments described below are intended to facilitate the understanding of the present invention and do not have any limiting effect on the present invention.

[0037] The present invention adopts a one-step synthesis method to prepare chiral gold nanoparticles. The material uses chiral glutathione (L-GSH and D-GSH) as thiol groups, and the pH of the system is adjusted by adding sodium hydroxide to prepare chiral gold nanomaterials with uniform particle size, good water solubility and stable optical properties.

[0038] Comparative Example 1

[0039] The chiral ligand reaction solution was obtained by mixing 125 μL of tetrachloroauric acid trihydrate solution (477 mM) with 100 mL of L-GSH or D-GSH solution (0.15 mM). The racemic ligand was obtained by mixing 50 mL of L-GSH (0.15 mM) and 50 mL of D-GSH (0.15 mM) solution and then adding 125 μL of tetrachloroauric acid trihydrate solution (477 mM) to obtain a racemic reaction solution. After stirring the above reaction solution at 240 rpm for 30 minutes at room temperature, 146 μL of sodium hydroxide solution (2 M) was added dropwise to adjust the system pH to 11, and then stirred for another 5 minutes. Subsequently, it was placed at room temperature for 11 hours. The free GSH molecules in the solution were removed by centrifugation at 13000 × g for 25 minutes, and then the material was washed 3 times.

[0040] However, this method has poor reproducibility and the particle sizes of different experimental batches are different.

[0041] Considering that reaction temperature is a key factor in controlling the particle size of the material, the reaction temperature of the experimental system was controlled to investigate the particle size of the obtained product.

[0042] Comparative Example 2

[0043] 125 μL of tetrachloroauric acid trihydrate solution (477 mM) was mixed with 100 mL of L-GSH solution (0.15 mM). After stirring at 240 rpm for 30 minutes at room temperature, 146 μL of sodium hydroxide solution (2 M) was added dropwise to adjust the pH of the system to 11, and then stirred for another 5 minutes. Subsequently, it was placed in a 27°C water bath for 11 hours. Free GSH molecules in the solution were removed by centrifugation at 13000 × g for 25 minutes, and then the material was washed 3 times, and the precipitate was dispersed in an aqueous solution and stored at 4°C for later use.

[0044] After the reaction, the hydrated particle size of the material was measured using a particle size analyzer. The results are as follows Figure 1 Middle (a).

[0045] Example 1

[0046] 125 μL of tetrachloroauric acid trihydrate solution (477 mM) was mixed with 100 mL of L-GSH solution (0.15 mM). After stirring at 240 rpm for 30 minutes at room temperature, 146 μL of sodium hydroxide solution (2 M) was added dropwise to adjust the pH of the system to 11, and then stirred for another 5 minutes. Subsequently, it was placed in a 37°C water bath for 11 hours. Free GSH molecules in the solution were removed by centrifugation at 13000 × g for 25 minutes, and then the material was washed 3 times to obtain left-handed gold nanoparticles (L-AuNPs). The precipitate was dispersed in an aqueous solution and stored at 4°C for later use.

[0047] After the reaction, the hydrated particle size of the material was measured using a particle size analyzer. The results are as follows Figure 1 In (b), the prepared gold nanomaterials have uniform size distribution.

[0048] Example 2

[0049] 125 μL of tetrachloroauric acid trihydrate solution (477 mM) was mixed with 100 mL of D-GSH solution (0.15 mM). After stirring at 240 rpm for 30 minutes at room temperature, 146 μL of sodium hydroxide solution (2 M) was added dropwise to adjust the pH of the system to 11, and then stirred for another 5 minutes. Subsequently, it was placed in a 37°C water bath for 11 hours. The free GSH molecules in the solution were removed by centrifugation at 13000 × g for 25 minutes, and then the material was washed 3 times to obtain right-handed gold nanoparticles (D-AuNPs). The precipitate was dispersed in an aqueous solution and stored at 4°C for later use.

[0050] Example 3

[0051] 125 μL of tetrachloroauric acid trihydrate solution (477 mM) was mixed with 100 mL of racemic solution (a mixed solution of 50 mL of L-GSH (0.15 mM) and 50 mL of D-GSH (0.15 mM)). After stirring at 240 rpm for 30 minutes at room temperature, 146 μL of sodium hydroxide solution (2 M) was added dropwise to adjust the pH of the system to 11, and then stirred for another 5 minutes. Subsequently, it was placed in a 37°C water bath for 11 hours. The free GSH molecules in the solution were removed by centrifugation at 13000 × g for 25 minutes, and then the material was washed 3 times to obtain racemic nanogold (DL-AuNPs), and the precipitate was dispersed in an aqueous solution and stored at 4°C for later use.

[0052] Figure 2 This is a scanning electron microscope image of the chiral gold nanomaterial prepared in Example 1-3. The chiral gold nanomaterial prepared in Example 1-3 has a stable morphology, a uniform size distribution, and a particle size of about 7 nm.

[0053] Figure 3 The spectra of the chiral gold nanomaterials prepared in Examples 1-3 show that L-AuNPs, D-AuNPs and DL-AuNPs have obvious SPR peaks at around 520 nm and have excellent optical activity. The CD signals of L-AuNPs and D-AuNPs are mirror-symmetrical.

[0054] Cytotoxicity and anti-inflammatory activity testing of chiral gold nanomaterials:

[0055] The present invention adopts CCK8 method to evaluate the effect of chiral gold nanomaterials on the cell activity of human bronchial epithelial cells (BEAS-2B), examines the biocompatibility and toxicity of the materials, and further uses qPCR to examine the relative change levels of the materials on the mRNA of CXCL2, CCL4 and COX-2 secreted by macrophages (RAW264.7).

[0056] The specific plan is: BEAS-2B cells are cultured at 1×10 5 The number of cells was inoculated into a 96-well cell culture plate and cultured overnight at 37 °C and 5% CO2. The next day, when the cell density reached about 80%, the cells were rinsed with PBS, and then treated with L-AuNPs, D-AuNPs and DL-AuNPs of different concentrations (0, 5, 10, 20, 40, 80 μg / mL) prepared with complete culture medium containing 10% FBS for 24 hours. The culture medium was aspirated, the cells were gently rinsed with PBS, 100 μL of CCK8 working solution was added, and the cells were placed in a cell culture incubator for another 2 hours. Finally, the OD value of each sample was measured at 450 nm and 690 nm using an enzyme reader, and the absorbance at 690 nm was used as correction. The cell viability was calculated after normalization of the blank group. The calculation formula is as follows: Cell viability = (OD 450 -OD 690 ) (experimental group) / (OD 450 -OD 690 ) (blank group) × 100%.

[0057] Figure 4 The effect of L-AuNPs, D-AuNPs and DL-AuNPs on the activity of BEAS-2B cells. When the concentration reached 80 μg / mL, the cells could still maintain good activity, indicating that the toxicity of gold nanomaterials modified with glutathione was low and would not cause serious toxic reactions. The biocompatibility of racemic materials (DL-AuNPs) was poor compared with that of left-handed (L-AuNPs) and right-handed (D-AuNPs) gold nanomaterials, so the anti-inflammatory activity of racemic materials was not considered.

[0058] For the in vitro study of the anti-inflammatory activity of the material, the present invention selected mouse mononuclear macrophages (RAW264.7) to establish a lipopolysaccharide (LPS)-induced inflammatory response model. The cells were cultured at 2×10 6The cells were inoculated into 6-well plates at a concentration of 100 μg / mL and cultured overnight until the cell density was about 80%. The cells were pre-exposed to 40 μg / mL L-AuNPs and D-AuNPs for 4 hours, and then 1 μg / mL lipopolysaccharide (LPS) was added to co-stimulate the cells for 20 hours. After removing the culture medium, RNA was extracted with Trizol, and the RNA concentration was determined by nanodrop 2000, and then reverse transcribed to cDNA. Finally, a 10 μL reaction system was prepared according to the requirements of the real-time fluorescence quantitative PCR kit, and the LIGHTCYCLER 480II fluorescence quantitative PCR system was used to detect according to the set reaction program.

[0059] The present invention uses glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal reference for relative quantification of CXCL2, CCL4 and COX-2 expression levels.

[0060] Figure 5-Figure 7 The anti-inflammatory activity of L-AuNPs and D-AuNPs showed that both L-AuNPs and D-AuNPs could significantly reduce the inflammatory factors produced by RAW264.7 stimulated by LPS, and the anti-inflammatory effect of L-AuNPs was stronger, which was significantly different from that of D-AuNPs.

[0061] For the anti-inflammatory pathway of the in vitro research material, the present invention pre-exposed the cells with 40 μg / mL L-AuNPs for 1 hour, and then added 1 μg / mL lipopolysaccharide (LPS) to co-stimulate the cells for 0.5 hours. After the exposure, protein was extracted from the cells, the protein was quantified using a BCA kit, and then the target protein was separated by SDS-PAGE, and finally the target protein content was detected by incubation with antibodies. Western blot results showed that LPS stimulation activated the NF-κB and MAPK pathways, which was specifically manifested by increased phosphorylation levels of p65 and p38 proteins. After treatment with L-gold nanoparticles, the phosphorylation level of p65 protein decreased, but the phosphorylation level of p38 did not change, indicating that the L-gold nanomaterial had no effect on the MAPK pathway, but played an anti-inflammatory role by inhibiting the NF-κB pathway.

[0062] Figure 8 The figure shows the changes in the phosphorylation levels of p65 and p38 proteins after treatment with L-AuNPs. L-AuNPs can significantly inhibit the phosphorylation level of p65 protein, but has no effect on the phosphorylation level of p38 protein.

[0063] Chiral gold nanomaterials for the treatment of sepsis:

[0064] The present invention establishes a sepsis model by intraperitoneal injection of LPS, purchases 20 C57 black mice (8 weeks old), and randomly divides the mice into 3 groups. 100 μL of saline, L-AuNPs, and D-AuNPs are injected into the peritoneal cavity of the two groups of mice, respectively. The second exposure is performed 1 hour after the injection, and the mice in the same group are randomly divided into two groups again. One group is injected with saline as a control, and the other group is injected with LPS as an experimental group for sepsis modeling. 4 hours after the second injection, the mice are killed and serum samples are collected. The serum samples collected in the experiment are used to determine the content of IL-1β and TNF-α in the serum by enzyme-linked immunosorbent assay (ELISA). Fig. 9 , Fig.10 The content of inflammatory factors in the serum of mice was measured by the L-AuNPs treatment group, which significantly reduced the content of inflammatory factors in the serum of septic mice, while the therapeutic effect of D-AuNPs was weaker.

[0065] In summary, the present invention prepares L-AuNPs, D-AuNPs and DL-AuNPs with a particle size of about 7 nm by a simple one-step synthesis method. The present invention establishes an LPS-induced cellular inflammatory response model to prove that the chiral material synthesized by the present invention can effectively reduce the production of inflammatory chemokines, has potential anti-inflammatory ability, and L-AuNPs has higher anti-inflammatory activity than D-AuNPs, and the chirality difference is significant. Further study of the anti-inflammatory pathway of left-handed gold nanomaterials showed that it targets the NF-κB pathway, can significantly reduce the phosphorylation level of p65, inhibit the activation of the NF-κB pathway, and has no effect on the MAPK pathway. In the LPS-induced mouse sepsis model, L-AuNPs have better anti-inflammatory and anti-injury abilities than D-AuNPs, showing good therapeutic effects.

[0066] The embodiments described above provide a detailed description of the technical solutions and beneficial effects of the present invention. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, supplements and equivalent substitutions made within the scope of the principles of the present invention should be included in the protection scope of the present invention.

Claims

1. Application of a chiral gold nanomaterial targeting NF-κB pathway in the preparation of anti-inflammatory drugs, It is characterized in that The preparation method of the chiral gold nanomaterial comprises: uniformly mixing a tetrachloroauric acid aqueous solution and a thiol-containing chiral ligand solution, then dropwise adding a sodium hydroxide solution, and obtaining the chiral gold nanomaterial after incubation treatment; The chiral ligand containing thiol group is L-glutathione; The anti-inflammatory drug is a drug for relieving and / or treating sepsis.

2. Use of the chiral gold nanomaterial targeting the NF-κB pathway according to claim 1 in the preparation of anti-inflammatory drugs, It is characterized in that In the reaction system of the incubation treatment, the molar ratio of tetrachloroauric acid to the chiral ligand is 3-5:

1.

3. Use of the chiral gold nanomaterial targeting the NF-κB pathway according to claim 1 in the preparation of anti-inflammatory drugs, It is characterized in that Sodium hydroxide solution was added dropwise to adjust the pH value of the reaction system to 10-12.

4. Use of the chiral gold nanomaterial targeting the NF-κB pathway according to claim 1 in the preparation of anti-inflammatory drugs, It is characterized in that The incubation temperature is 27-40℃.

5. Use of the chiral gold nanomaterial according to claim 1 or 4 in the preparation of anti-inflammatory drugs, It is characterized in that The incubation time is 10-24h.

6. Use of the chiral gold nanomaterial targeting the NF-κB pathway according to claim 1 in the preparation of anti-inflammatory drugs, It is characterized in that The particle size of the chiral gold nanomaterial is 6-8nm.

Citation Information

Patent Citations

  • Preparation method and application of hand-shaped gold nanoclusters for inhibiting MGC-803 cells

    CN103933583A

  • Method for preparing chiral silver nano-cluster by using chiral cysteine and silver nitrate

    CN116021027A

  • Application of chiral nanometer material based on microglial cell inflammatory aging regulation in preparation of medicine for treating Alzheimer's disease

    CN116212049A

  • Nano-drug for regulating macrophage M2 type polarization by targeting mitochondria as well as preparation method and application of nano-drug

    CN117797268A

  • Pharmaceutical composition for treating inflammatory disease and immune disease comprising metal nanoparticles having Anti-inflammatory activity as an effective ingredient

    KR1020090080855A